abstract |
The present invention relates to a compound of formula (I) wherein Ar 1 is aryl or heteroaryl; Ar 2 is aryl or heteroaryl; R 1 is hydrogen, halogen, hydroxy, lower alkyl, lower alkoxy, lower alkyl substituted by halogen, lower alkoxy substituted by halogen, S-lower alkyl, -S(O) 2 -lower alkyl, -S(O) 2 -di- lower alkyl amino, cyano, amino, mono or di- lower alkyl amino, C(O)-lower alkyl, NHC(O)-lower alkyl, cycloalkyl, heterocyclyl, or is heteroaryl, optionally substituted by lower alkyl; R 2 is hydrogen, halogen, lower alkyl, lower alkoxy, lower alkyl substituted by halogen or cyano; R 3 is hydrogen, halogen, lower alkyl or lower alkyl substituted by halogen; n is 1, 2 or 3; in case n is 2 or 3, R 1 may be the same or different; o is 1, 2 or 3; in case o is 2 or 3, R 2 may be the same or different; p is 1, 2 or 3; in case p is 2 or 3, R 4 may be the same or different; or to a pharmaceutically active salt, to all stereoisomeric forms, including individual diastereoisomers and enantiomers as well as to racemic and non-racemic mixtures thereof. It has been found that the present compounds are high potential NK-3 receptor antagonists for the treatment of depression, pain, psychosis, Parkinson's disease, schizophrenia, anxiety and attention deficit hyperactivity disorder (ADHD). |